X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
ODM-208/MK5684 is an investigational CYP11A1 inhibitor, which is being evaluated in combination with hormone replacement therapy under phase 3 clinical trials for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Lead Product(s): MK5684,Dexamethasone,Fludrocortisone Acetate
Therapeutic Area: Oncology Product Name: ODM-208
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2024
Cophex 2024
Not Confirmed
Contact SupplierDetails:
ODM-208 (or MK-5684) is an investigational oral, non-steroidal and selective inhibitor of the CYP11A1 enzyme discovered and developed by Orion for the treatment of hormone-dependent cancers, such as metastatic castration-resistant prostate cancer.
Lead Product(s): MK-5684,Dexamethasone,Hydrocortisone
Therapeutic Area: Oncology Product Name: ODM-208
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2023
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Reddy-Lenalidomide capsules are available in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths, each in blister packs.
Lead Product(s): Lenalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Revlimid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2021
Details:
Dr. Reddy's Laboratories launched Ciprofloxacin0.3%and Dexamethasone 0.1% Otic Suspension,USP,a therapeutic equivalent generic version ofCiprodex®(ciprofloxacin 0.3% and dexamethasone 0.1%)Otic Suspension,approved by the U.S. Food andDrug Administration (USFDA).
Lead Product(s): Ciprofloxacin,Dexamethasone
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2020
Details:
NICE recommends Ozurdex® (dexamethasone) as an option for treating visual impairment caused by DMO in adults, only when it has not responded well enough to, or they cannot have non-corticosteroid therapy.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: Ozurdex
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2022
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Sarclisa (isatuximab) is a antibody that binds to a specific epitope on the CD38 receptor on multiple myeloma (MM) cells. It is being evaluated in phase 3 clinical trials in combination with carfilzomib, lenalidomide & dexamethasone (KRd) for the treatment ofMultiple Myeloma.
Lead Product(s): Isatuximab,Pomalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Sarclisa
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Latest results from Phase 3 IKEMA clinical trial for Sarclisa®(isatuximab-irfc) in combination with carfilzomib and dexamethasone demonstrated a median PFS of 35.7 months, compared to 19.2 months in patients treated with Kd alone.
Lead Product(s): Isatuximab-irfc,Pomalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Sarclisa
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2022
Cophex 2024
Not Confirmed
Contact Supplier
Details:
For the Sarclisa® subcutaneous formulation delivery, Sanofi has partnered with drug delivery technology innovator company to advance the development of a subcutaneous delivery for Sarclisa® with the goal of offering a unique patient-centric treatment experience.
Lead Product(s): Isatuximab,Pomalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Sarclisa
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Blackstone Life Sciences
Deal Size: $330.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 15, 2022
Cophex 2024
Not Confirmed
Contact SupplierDetails:
SARCLISA® continues to be evaluated in multiple ongoing Phase 3 clinical trials in combination with current standard treatments across the MM treatment continuum. It is also under investigation for the treatment of other hematologic malignancies and solid tumours.
Lead Product(s): Isatuximab-irfc,Pomalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Sarclisa
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2021
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Sarclisa is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity.
Lead Product(s): Isatuximab-irfc,Pomalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Sarclisa
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2021
Cophex 2024
Not Confirmed
Contact SupplierDetails:
The decision follows the Phase III IKEMA trial, which featured 302 patients with relapsed multiple myeloma across 69 centers spanning 16 countries. The study found that Sarclisa added to Kd reduced the risk of disease progression or death by 45%, versus Kd alone.
Lead Product(s): Isatuximab-irfc,Pomalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Sarclisa
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2021
Cophex 2024
Not Confirmed
Contact SupplierDetails:
CHMP issues positive opinion for second indication for Sarclisa in combination with carfilzomib and dexamethasone for adult patients with multiple myeloma who have received at least one prior therapy.
Lead Product(s): Isatuximab,Carfilzomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Sarclisa
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2021
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Sarclisa (isatuximab) has been recommended in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma who have received three prior lines of treatment, including lenalidomide and proteasome inhibitor.
Lead Product(s): Isatuximab-irfc,Pomalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Sarclisa
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2020
Cophex 2024
Not Confirmed
Contact SupplierDetails:
SARCLISA™ in combination with pom-dex significantly reduced the risk of disease progression or death by 40% compared to pom-dex alone in a pivotal trial.
Lead Product(s): Isatuximab,Pomalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Sarclisa
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2020
Cophex 2024
Not Confirmed
Contact SupplierDetails:
EC approval based on data from first randomized Phase 3 trial (ICARIA-MM) to report results evaluating an anti-CD38 monoclonal antibody combined with pomalidomide and dexamethasone (pom-dex).
Lead Product(s): Isatuximab,Pomalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Sarclisa added to carfilzomib and dexamethasone (Sarclisa combination) reduced risk of disease progression or death by 47% versus standard of care carfilzomib and dexamethasone (Kd) alone.
Lead Product(s): Isatuximab,Carfilzomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Addition of Sarclisa significantly reduced the risk of disease progression or death compared to carfilzomib and dexamethasone alone.
Lead Product(s): Isatuximab,Carfilzomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2020
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Positive CHMP opinion based on data from ICARIA-MM, the first randomized Phase 3 trial to evaluate an anti-CD38 in combination with pom-dex.
Lead Product(s): Isatuximab,Pomalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2020
Cophex 2024
Not Confirmed
Contact SupplierDetails:
Ocrevus (ocrelizumab) is an investigational twice-yearly, 10-minute subcutaneous injection, humanised monoclonal antibody designed to target CD20-positive B cells to treat patients with progressive and relapsing forms of MS.
Lead Product(s): Ocrelizumab,Dexamethasone,Desloratadine
Therapeutic Area: Neurology Product Name: Ocrevus
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2024
Details:
Under the collaboration, Vector will distribute Pepaxti (melphalan flufenamide), indicated in combination with dexamethasone, to patients in the MENA region for the treatment of patients with multiple myeloma.
Lead Product(s): Melphalan Flufenamide,Dexamethasone
Therapeutic Area: Oncology Product Name: Pepaxti
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Vector Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 30, 2024
Details:
Under the agreement, Vector will distribute Pepaxti (melphalan flufenamide), indicated in combination with dexamethasone, in the MENA region for the treatment of patients with multiple myeloma.
Lead Product(s): Melphalan Flufenamide,Dexamethasone
Therapeutic Area: Oncology Product Name: Pepaxti
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Vector Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 27, 2024
Details:
Ciprofloxacin and dexamethasone otic suspension is a combination product which is indicated for the treatment of Acute Otitis Externa in pediatric (age 6 months and older), adult & elderly patients due to Staphylococcus aureus and Pseudomonas aeruginosa.
Lead Product(s): Ciprofloxacin,Dexamethasone
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Ciprodex-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024
Details:
Blenrep (belantamab mafodotin-blmf) is a humanized anti-BCMA antibody/drug conjugate. It is being evaluated in phase 3 clinical trials in combination with pomalidomide, bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Lead Product(s): Belantamab Mafodotin,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Blenrep
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2024
Details:
Dextenza (dexamethasone) is a corticosteroid intracanalicular insert, that acts as a glucocorticoid receptor agonist. It is indicated for the treatment of ocular inflammation and pain following ophthalmic surgery.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: Dextenza
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2024
Details:
Blenrep (belantamab mafodotin-blmf) is a humanized anti-BCMA antibody/drug conjugate. It is being evaluated in phase 3 clinical trials in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Lead Product(s): Belantamab Mafodotin,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Blenrep
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2024
Details:
STAR-LLD is a continuous delivery lenalidomide (LLD), which is under phase 1 clinical development to expand and replace the standard of care for the most common blood cancers, multiple myeloma (MM), and chronic lymphocytic leukemia (CLL).
Lead Product(s): Lenalidomide,Dexamethasone,Bortezomib
Therapeutic Area: Oncology Product Name: STAR-LLD
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
Through the acquisition, Astellas has acquired PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor being developed by Propella to treat prostate cancer.
Lead Product(s): Abiraterone Decanoate,Dexamethasone,Prednisone
Therapeutic Area: Oncology Product Name: PRL-02
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: $175.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition December 21, 2023
Details:
OCS-01 (dexamethasone) is a glucocorticoid receptor agonist, which is being evaluated in phase 3 clinical trials for the treatment of inflammation and pain following cataract surgery.
Lead Product(s): Dexamethasone
Therapeutic Area: Neurology Product Name: OCS-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
OCS-01 (dexamethasone) is a novel, high concentration (15 mg/ml), topical formulation of dexamethasone. It is under phase 3 clinical development for the treatment of Diabetic Macular Edema.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: OCS-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
CFT7455 is an orally bioavailable MonoDAC degrader designed to be highly potent and selective against its intended targets of IKZF1 and IKZF3 and overcome shortcomings of currently approved therapies to treat multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL).
Lead Product(s): CFT7455,Dexamethasone
Therapeutic Area: Oncology Product Name: CFT7455
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
Blenrep (belantamab mafodotin) is a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate. It is being evaluated for the treatment of relapsed/refractory multiple myeloma.
Lead Product(s): Belantamab Mafodotin,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Blenrep
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
STAR-LLD is a continuous delivery lenalidomide in development to expand and replace the standard of care for the most common blood cancers, multiple myeloma (MM) and chronic lymphocytic leukemia (CLL).
Lead Product(s): Lenalidomide,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: STAR-LDD
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
Through the acquisition of Propella, Astellas will acquire PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor being developed by Propella to treat prostate cancer.
Lead Product(s): Abiraterone Decanoate,Prednisone,Dexamethasone
Therapeutic Area: Oncology Product Name: PRL-02
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: $175.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition November 15, 2023
Details:
The Company remains focused and committed to the completion of its Phase 1b STAR-LLD clinical trial in multiple myeloma study in order to bring patients a potentially superior delivery of continuous subcutaneous administration of lenalidomide.
Lead Product(s): Lenalidomide,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: STAR-LDD
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Healthwell Acquisition Corp. I
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination November 03, 2023
Details:
TTP488 (azeliragon), is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). It is being investigated for the treatment of refractory to first-line treatment of metastatic pancreatic cancer.
Lead Product(s): Azeliragon,Dexamethasone
Therapeutic Area: Oncology Product Name: TTP488
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
Dextenza (dexamethasone), a corticosteroid intracanalicular insert, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: Dextenza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ocular Therapeutix
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2023
Details:
SX600 (dexamethasone) is a novel formulation of extended-release microspheres designed for transforaminal epidural injection in the management of sciatica pain.
Lead Product(s): Dexamethasone
Therapeutic Area: Musculoskeletal Product Name: SX600
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
Azeliragon is an orally administered capsule, taken once daily, that inhibits interactions of RAGE with certain ligands, including HMGB1 and S100 proteins in the tumor microenvironment.
Lead Product(s): Azeliragon,Dexamethasone
Therapeutic Area: Oncology Product Name: TTP488
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Details:
Under the agreement, Hansoh will be exclusively responsible for commercialization of Xpovio (selinexor), world's first approved orally-available, selective inhibitor of the nuclear export protein XPO1, in the mainland of China for relapsed or refractory multiple myeloma.
Lead Product(s): Selinexor,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hansoh Pharma
Deal Size: $101.5 million Upfront Cash: $27.6 million
Deal Type: Collaboration August 10, 2023
Details:
OCS-01 eye drops, a novel, once-daily, high concentration, preservative-free, topical OPTIREACH® formulation of dexamethasone is being developed for the treatment of inflammation and pain following ocular surgery.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: OCS-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
OCS-01 is developed using the Optireach® solubilizing technology, a proprietary platform that enables the formulation of drugs as topical eye drop treatment with cystoid macular edema.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: OCS-01
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2023
Details:
OCREVUS (ocrelizumab) is a humanised monoclonal antibody designed to target CD20-positive B cells, which is being investigated as a a 10-minute subcutaneous injection, for the treatment of multiple sclerosis.
Lead Product(s): Ocrelizumab,Dexamethasone,Desloratadine
Therapeutic Area: Neurology Product Name: Ocrevus
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2023
Details:
The company intends to use the net proceeds to fund the development of CCS1477 (inobrodib), its p300/CBP inhibitor to treat specific types of cancer including haematological malignancies and multiple myeloma.
Lead Product(s): Inobrodib,Pomalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: CCS1477
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Financing July 11, 2023
Details:
MDX-1097 (kappamab) targets a receptor called Kappa Myeloma Antigen (KMA) found only on the surface of myeloma cells in in combination with lenalidomide and dexamethasone in kappa-type multiple myeloma patients who had relapsed or become refractory to other treatment options.
Lead Product(s): KappaMab,Lenalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: MDX-1097
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
Oculis will fund its development programs in Diabetic Macular Edema and other ophthalmic indications, including OCS-01's NDA enabling activities. OCS-01 (dexamethasone) eye drops is developed using the Optireach® solubilizing technology for the treatment of DME.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: OCS-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $40.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 31, 2023
Details:
Dextenza (dexamethasone), a corticosteroid intracanalicular insert, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: Dextenza
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ocular Therapeutix
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
XPOVIO® (selinexor) is the first and only selective inhibitor of nuclear export inhibitor approved by the Therapeutic Goods Administration of Australia for patients with relapsed and/or refractory multiple myeloma and in triple class refractory R/R MM.
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
OCS-01 (dexamethasone) has been developed using the OPTIREACH solubilizing nanoparticle technology, enabing the formulation of drugs as non-invasive topical treatments, a longer residence time on the eye surface and enhances their bioavailability in the relevant eye tissues.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: OCS-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2023
Details:
Under the terms of the licensing agreement, AstraZeneca will be granted an exclusive global license to research, develop, and commercialize LM-305, a pre-clinical stage antibody drug conjugate (ADC) targeting G protein-coupled receptor, class C, group 5, member D (GPRC5D).
Lead Product(s): LM-305,Dexamethasone
Therapeutic Area: Oncology Product Name: LM-305
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $600.0 million Upfront Cash: $55.0 million
Deal Type: Licensing Agreement May 12, 2023
Details:
Dextenza (dexamethasone), a corticosteroid, has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage and migration of inflammatory cells.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: Dextenza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
